KM Biologics, a Meiji group company, has acquired an exclusive option to French biopharma Osivax’s broad-spectrum universal influenza vaccine candidates in Japan, the two companies said on September 10. Under their pact, KM Biologics holds an exclusive option to exercise…
To read the full story
Related Article
- Meiji Invests in French Vaccine Player Osivax
March 5, 2025
BUSINESS
- Astellas Sees Xtandi Patent Cliff a “Critical Phase,” Steps Up Board Oversight via EPM
December 10, 2025
- PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
- SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
December 10, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





